Prednisolone neuroprotective therapy in age-related macular degeneration.
134 patients with Age-related Macular Degeneration (AMD) (aging 47-75 years) were treated in therapy procedure with parabulbar injections of Methylprednisolone Acetate and Prednisolone Acetate. In the first group of patients with AMD (n = 71 patients) were treated with Methylprednisolone acetate, and second group (n = 63 patients) with Prednisolone acetate. Each patient was given doses of 60 mg, through two weeks, 10 mg every second day. It's estimated in all patients ameliorate in macular threshold, so that it's in the group with Methylprednisolone treatment, ameliorate effect begins after first week, than in second group, treated with Prednisolone, initial ameliorate effect is after second week. Complete effect in both groups is after 2 months. It can be concluded that the treatment of AMD with glucocorticoids has the ameliorate effect in vision loss and it is decided that earlier effect in the group treated with Methylprednisolone, is probably of higher affinity for glucocorticoid receptors.
Vojniković
Bozidar
B
Eye Polyclinic "Dr. B. Vojniković", Rijeka, Croatia. decv@decv.com
Spanjol
Josip
J
D000368:Aged; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy*; D008775:Methylprednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077555:Methylprednisolone Acetate; D008875:Middle Aged; D018696:Neuroprotective Agents / Q000627:therapeutic use; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D005938:Glucocorticoids; D018696:Neuroprotective Agents; D000077555:Methylprednisolone Acetate; C009935:prednisolone acetate; D011239:Prednisolone; D008775:Methylprednisolone